Detalhe da pesquisa
1.
The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis.
Anticancer Drugs
; 33(1): e635-e643, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34371506
2.
Influence of Helicobacter pylori infection on PD-1/PD-L1 blockade therapy needs more attention.
Helicobacter
; 27(2): e12878, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35112435
3.
Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers.
Ann Diagn Pathol
; 35: 69-76, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29843069
4.
Safety and efficacy evaluation of personalized exercise prescription during chemotherapy for lung cancer patients.
Thorac Cancer
; 15(11): 906-918, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38462754
5.
Clinical observation of peripheral nerve injury in 2 patients with cancer after radiotherapy.
Contemp Oncol (Pozn)
; 17(2): 196-9, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23788990
6.
A Bibliometric Analysis on the Research Trend of Exercise and the Gut Microbiome.
Microorganisms
; 11(4)2023 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37110325
7.
ABSDELL Model: Development and Internal Validation of a Risk Prediction Model of LVEF Decline in Breast Cancer Patients Treated With Trastuzumab.
Clin Breast Cancer
; 23(1): 23-31, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36384817
8.
Corrigendum: Nitazoxanide, an antiprotozoal drug, reduces bone loss in ovariectomized mice by inhibition of RANKL-induced osteoclastogenesis.
Front Pharmacol
; 14: 1247393, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37564185
9.
Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy.
Biomark Res
; 10(1): 67, 2022 Aug 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36042469
10.
Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced esophageal squamous cell cancer: A case report.
Thorac Cancer
; 13(3): 497-501, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35014762
11.
Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic-pharmacodynamic model of neutropenia.
Cancer Chemother Pharmacol
; 90(6): 489-497, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36271947
12.
Nitazoxanide and related thiazolides induce cell death in cancer cells by targeting the 20S proteasome with novel binding modes.
Biochem Pharmacol
; 197: 114913, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35032461
13.
Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer.
Asia Pac J Oncol Nurs
; 8(5): 586-590, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34527790
14.
Nitazoxanide, an Antiprotozoal Drug, Reduces Bone Loss in Ovariectomized Mice by Inhibition of RANKL-Induced Osteoclastogenesis.
Front Pharmacol
; 12: 781640, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34955850
15.
Alisol A is potentially therapeutic in human breast cancer cells.
Oncol Rep
; 44(3): 1266-1274, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32582967
16.
Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin-induced apoptosis.
Thorac Cancer
; 10(4): 918-929, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30883017
17.
The deregulation of miR-133b is associated with poor prognosis in bladder cancer.
Pathol Res Pract
; 215(2): 354-357, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30591241
18.
MELK is a novel therapeutic target in high-risk neuroblastoma.
Oncotarget
; 9(2): 2591-2602, 2018 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29416794
19.
[Clinical study of aromatase inhibitors in advanced breast cancer].
Beijing Da Xue Xue Bao Yi Xue Ban
; 39(2): 193-6, 2007 Apr 18.
Artigo
em Zh
| MEDLINE | ID: mdl-17440599
20.
[Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients].
Zhonghua Zhong Liu Za Zhi
; 28(11): 848-51, 2006 Nov.
Artigo
em Zh
| MEDLINE | ID: mdl-17416008